Multimodal management of muscle-invasive bladder cancer

Current Problems in Cancer

Volumn 38, Issue 3, 2014, Pages 80-108

  Park, Jong Chul ^a   Citrin, Deborah E ^b   Agarwal, Piyush K ^b   Apolo, Andrea B ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; VASCULOTROPIN; VINBLASTINE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DOSE DENSIFICATION; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PELVIS LYMPH NODE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; URINARY DIVERSION; URINE CYTOLOGY; CARCINOMA; CLINICAL TRIAL (TOPIC); HUMAN; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; RISK FACTOR; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84906055473     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2014.06.001     Document Type: Article

References (196)

1. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27(3):289-293.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
3. Freedman N.D., Silverman D.T., Hollenbeck A.R., et al. Association between smoking and risk of bladder cancer among men and women. J Am Med Assoc 2011, 306(7):737-745.
4. Zeegers M.P., Swaen G.M., Kant I., et al. Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med 2001, 58(9):590-596.
5. Gaertner R.R., Trpeski L., Johnson K.C. A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control 2004, 15(10):1007-1019.
6. Apolo A.B., Dahut W. Bladder cancer. The Bethesda Handbook of Clinical Oncology 2014, 208-218. Lippincott Williams & Wilkins, Philadelphia. C. Allegra (Ed.).
7. Agarwal P.K., Black P.C., Kamat A.M. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 2008, 26(1):39-44.
8. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66(6 Suppl 1):4-34.
9. Raghavan D. Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol Oncol 2003, 21(6):468-474.
10. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349(9):859-866.
11. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19(3):666-675.
12. Apolo A.B., Grossman H.B., Bajorin D., et al. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol 2012, 30(6):772-780.
13. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21(4):690-696.
14. Karl A., Carroll P.R., Gschwend J.E., et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 2009, 55(4):826-835.
15. Leissner J., Ghoneim M.A., Abol-Enein H., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 2004, 171(1):139-144.
16. Dhar N.B., Klein E.A., Reuther A.M., et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 2008, 179(3):873-878. [discussion 8].
17. Canter D., Guzzo T.J., Resnick M.J., et al. A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology 2009, 74(1):161-165.
18. Herr H.W., Faulkner J.R., Grossman H.B., et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004, 22(14):2781-2789.
19. Horsted F., West J., Grainge M.J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012, 9(7):e1001275.
20. Shabsigh A., Korets R., Vora K.C., et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009, 55(1):164-174.
21. Stimson C.J., Chang S.S., Barocas D.A., et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol 2010, 184(4):1296-1300.
22. Zippe C.D., Raina R., Massanyi E.Z., et al. Sexual function after male radical cystectomy in a sexually active population. Urology 2004, 64(4):682-685. [discussion 5-6].
23. Pruthi R.S., Nielsen M., Smith A., et al. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg 2010, 210(1):93-99.
24. Rozet F., Lesur G., Cathelineau X., et al. Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol 2008, 179(6):2170-2174. [discussion 4-5].
25. Schoenberg M.P., Walsh P.C., Breazeale D.R., et al. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 1996, 155(2):490-494.
26. Johar R.S., Hayn M.H., Stegemann A.P., et al. Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 2013, 64(1):52-57.
27. Marshall S.J., Hayn M.H., Stegemann A.P., et al. Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int 2013, 111(7):1075-1080.
28. Soler S., Delgado C., Ballaz A., et al. Unsuspected pulmonary embolism in patients with cancer. Thromb Res 2012, 129(suppl 1):S16-S19.
29. Holmes D.G., Thrasher J.B., Park G.Y., et al. Long-term complications related to the modified Indiana pouch. Urology 2002, 60(4):603-606.
30. Cancrini A., De Carli P., Pompeo V., et al. Lower urinary tract reconstruction following cystectomy: experience and results in 96 patients using the orthotopic ileal bladder substitution of Studer et al. Eur Urol 1996, 29(2):204-209.
31. Hautmann R.E., de Petriconi R., Gottfried H.W., et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999, 161(2):422-427. [discussion 7-8].
32. Stein J.P., Dunn M.D., Quek M.L., et al. The orthotopic T pouch ileal neobladder: experience with 209 patients. J Urol 2004, 172(2):584-587.
33. Carrion R., Arap S., Corcione G., et al. A multi-institutional study of orthotopic neobladders: functional results in men and women. BJU Int 2004, 93(6):803-806.
34. Madersbacher S., Mohrle K., Burkhard F., et al. Long-term voiding pattern of patients with ileal orthotopic bladder substitutes. J Urol 2002, 167(5):2052-2057.
35. Lee R.K., Abol-Enein H., Artibani W., et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int 2014, 113(1):11-23.
36. Parekh D.J., Donat S.M. Urinary diversion: options, patient selection, and outcomes. Semin Oncol 2007, 34(2):98-109.
37. Raghavan D., Shipley W.U., Garnick M.B., et al. Biology and management of bladder cancer. N Engl J Med 1990, 322(16):1129-1138.
38. Kaufman D.S. Challenges in the treatment of bladder cancer. Ann Oncol 2006, 17(suppl 5):v106-v112.
39. Shipley W.U., Cummings K.B., Coombs L.J., et al. 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging. J Urol 1982, 127(1):48-51.
40. Cole C.J., Pollack A., Zagars G.K., et al. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995, 32(2):331-340.
41. Crawford E.D., Das S., Smith J.A. Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am 1987, 14(4):781-787.
42. Neoadjuvant cisplatin for advanced bladder cancer. Cochrane Database Syst Rev 2000, (2):CD001426. Advanced Bladder Cancer Overview Collaboration.
43. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999, 354(9178):533-540.
44. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133(3):403-407.
45. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992, 10(7):1066-1073.
46. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8(6):1050-1055.
47. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003, 361(9373):1927-1934. Advanced Bladder Cancer Meta-analysis Collaboration.
48. Winquist E., Kirchner T.S., Segal R., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004, 171(2 Pt 1):561-569.
49. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18(17):3068-3077.
50. Yeshchina O., Badalato G.M., Wosnitzer M.S., et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 2012, 79(2):384-390.
51. Dash A., Pettus J.A., Herr H.W., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008, 113(9):2471-2477.
52. Fairey A.S., Daneshmand S., Quinn D., et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol 2013, 31(8):1737-1743.
53. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001, 19(10):2638-2646.
54. Plimack E.R., Hoffman-Censits J., Viterbo R., et al. Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: results of a multicenter phase II study. J Clin Oncol 2012, 30. [abstr 4526].
55. Qu A., Jacobus S., Signoretti S., et al. Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease-free survival (DFS). J Clin Oncol 2013, (Suppl 15):31. [abstr 4530].
56. Siefker-Radtke A., Kamat A.M., Corn P., et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 2012, 30(suppl 5). [abstr 261].
57. Blick C., Hall P., Pwint T., et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 2012, 118(16):3920-3927.
58. Bamias A., Dafni U., Karadimou A., et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol 2013, 24(4):1011-1017.
59. Sahut D'Izarn M., Caumont Prim A., Planquette B., et al. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study. J Thromb Haemost 2012, 10(10):2032-2038.
60. Hussain M., Vaishampayan U., Du W., et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001, 19(9):2527-2533.
61. Smith D.C., Mackler N.J., Dunn R.L., et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol 2008, 180(6):2384-2388. [discussion 8].
62. deVere White R.W., Lara P.N., Goldman B., et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009, 181(6):2476-2480. [discussion 80-1].
63. Nagane M., Nishikawa R., Narita Y., et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012, 42(10):887-895.
64. Wood D.P. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. J Urol 2011, 186(6):2211-2212.
65. Donat S.M., Shabsigh A., Savage C., et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009, 55(1):177-185.
66. Studer U.E., Bacchi M., Biedermann C., et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994, 152(1):81-84.
67. Skinner D.G., Daniels J.R., Russell C.A., et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991, 145(3):459-464. [discussion 64-7].
68. Millikan R., Dinney C., Swanson D., et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19(20):4005-4013.
69. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005, 48(2):189-199. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, [discussion 99-201].
70. Svatek R.S., Shariat S.F., Lasky R.E., et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010, 16(17):4461-4467.
71. Paz-Ares L., Solsona E., Esteban E., et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010, 28(18S). [abstr LBA4518].
72. Cognetti F., Ruggeri E.M., Felici A., et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2012, 23(3):695-700.
73. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331(19):1259-1264.
74. Cote R.J., Esrig D., Groshen S., et al. p53 and treatment of bladder cancer. Nature 1997, 385(6612):123-125.
75. Stadler W.M., Lerner S.P., Groshen S., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011, 29(25):3443-3449.
76. Gallagher D.J., Milowsky M.I., Iasonos A., et al. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer 2009, 115(22):5193-5201.
77. David K.A., Milowsky M.I., Ritchey J., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007, 178(2):451-454.
78. Porter M.P., Kerrigan M.C., Donato B.M., et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011, 29(3):252-258.
79. Fedeli U., Fedewa S.A., Ward E.M. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 2011, 185(1):72-78.
80. Bochner B., Feifer A., Sperling D., et al. Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa). J Clin Oncol 2014, 32(suppl 4). [abstr 298].
81. Apolo A.B., Bochner B., Steinberg S., et al. Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO). J Clin Oncol 2012, 30(suppl 5). [abstr 298].
82. Konety B.R., Allareddy V., Herr H. Complications after radical cystectomy: analysis of population-based data. Urology 2006, 68(1):58-64.
83. Manoharan M., Ayyathurai R., Soloway M.S. Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU Int 2009, 104(9):1227-1232.
84. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001, 19(1):89-93.
85. Solsona E., Climent M.A., Iborra I., et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009, 55(4):911-919.
86. Knoedler J.J., Boorjian S.A., Kim S.P., et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol 2012, 188(4):1115-1119.
87. Holzbeierlein J.M., Lopez-Corona E., Bochner B.H., et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004, 172(3):878-881.
88. Smaldone M.C., Jacobs B.L., Smaldone A.M., et al. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 2008, 72(3):613-616.
89. Kassouf W., Swanson D., Kamat A.M., et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006, 175(6):2058-2062.
90. Capitanio U., Isbarn H., Shariat S.F., et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology 2009, 74(4):858-864.
91. Zhang M., Tao R., Zhang C., et al. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies. Urology 2010, 76(4):902-907.
92. Sternberg C.N., Pansadoro V., Calabro F., et al. Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer 2003, 97(7):1644-1652.
93. Duncan W., Quilty P.M. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986, 7(4):299-310.
94. van der Steen-Banasik E., Ploeg M., Witjes J.A., et al. Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study. Radiother Oncol 2009, 93(2):352-357.
95. Cooke P.W., Dunn J.A., Latief T., et al. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur Urol 2000, 38(3):279-286.
96. Perdona S., Autorino R., Damiano R., et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008, 112(1):75-83.
97. Gamal El-Deen H., Elshazly H.F., Abo Zeina E.A. Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer. J Egypt Natl Canc Inst 2009, 21(1):59-70.
98. Coppin C.M., Gospodarowicz M.K., James K., et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996, 14(11):2901-2907.
99. Hussain S.A., Stocken D.D., Peake D.R., et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004, 90(11):2106-2111.
100. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012, 366(16):1477-1488.
101. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993, 25(5):783-790.
102. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002, 60(1):62-67. [discussion 7-8].
103. Housset M., Maulard C., Chretien Y., et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993, 11(11):2150-2157.
104. Koga F., Kihara K. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol 2012, 19(5):388-401.
105. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002, 20(14):3061-3071.
106. Mitin T., Hunt D., Shipley W.U., et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013, 14(9):863-872.
107. Efstathiou J.A., Spiegel D.Y., Shipley W.U., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012, 61(4):705-711.
108. Kaufman D.S., Winter K.A., Shipley W.U., et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000, 5(6):471-476.
109. Kaufman D.S., Winter K.A., Shipley W.U., et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009, 73(4):833-837.
110. Mitin T., George A., Zietman A.L., et al. Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: a pooled analysis of RTOG 9906 and 0233. J Clin Oncol 2014, 32(suppl 4). [abstr 284].
111. Bellmunt J., Albanell J., Paz-Ares L., et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002, 95(4):751-757.
112. Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000, 18(18):3247-3255.
113. Bellmunt J., von der Maase H., Mead G.M., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012, 30(10):1107-1113.
114. Kim H.L., Steinberg G.D. Complications of cystectomy in patients with a history of pelvic radiation. Urology 2001, 58(4):557-560.
115. Eisenberg M.S., Dorin R.P., Bartsch G., et al. Early complications of cystectomy after high dose pelvic radiation. J Urol 2010, 184(6):2264-2269.
116. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998, 16(11):3576-3583.
117. Chen R.C., Shipley W.U., Efstathiou J.A., et al. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw 2013, 11(8):952-960.
118. Apolo A.B., Milowsky M., Bajorin D.F. Clinical states model for biomarkers in bladder cancer. Future Oncol 2009, 5(7):977-992.
119. Smith S.C., Baras A.S., Dancik G., et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011, 12(2):137-143.
120. Kim W.J., Kim E.J., Kim S.K., et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010, 9:3.
121. Blaveri E., Simko J.P., Korkola J.E., et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005, 11(11):4044-4055.
122. Riester M., Taylor J.M., Feifer A., et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012, 18(5):1323-1333.
123. Bochner B.H., Kattan M.W., et al. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006, 24(24):3967-3972. International Bladder Cancer Nomogram Consortium.
124. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507(7492):315-322. Cancer Genome Atlas Research Network.
125. Crew J.P., O'Brien T., Bicknell R., et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999, 161(3):799-804.
126. Inoue K., Slaton J.W., Karashima T., et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000, 6(12):4866-4873.
127. Jeon S.H., Lee S.J., Chang S.G. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep 2001, 8(6):1265-1267.
128. Bernardini S., Fauconnet S., Chabannes E., et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001, 166(4):1275-1279.
129. Kopparapu P.K., Boorjian S.A., Robinson B.D., et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 2013, 33(6):2381-2390.
130. Xia G., Kumar S.R., Hawes D., et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006, 175(4):1245-1252.
131. Rife C.C., Farrow G.M., Utz D.C. Urine cytology of transitional cell neoplasms. Urol Clin North Am 1979, 6(3):599-612.
132. Eissa S., Salem A.M., Zohny S.F., et al. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomark 2007, 3(6):275-285.
133. Urquidi V., Goodison S., Kim J., et al. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 2012, 79(5). 1185.e1-e6.
134. Chaudhary U., Golshayan A., Brisendine A., et al. Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2011, 29(suppl 7). [abstr 276].
135. Sonpavde G., Jian W., Liu H., et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009, 27(4):391-399.
136. Bellmunt J., Gonzalez-Larriba J.L., Prior C., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011, 22(12):2646-2653.
137. Gallagher D.J., Milowsky M.I., Gerst S.R., et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010, 28(8):1373-1379.
138. Grivas P.D., Daignault S., Tagawa S.T., et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2014, 120(5):692-701.
139. Galsky M.D., Hahn N.M., Powles T., et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013, 11(2):175-181.
140. Balar A.V., Iyer G., Apolo A.B., et al. Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol 2012, 30(Suppl 15). [abstr 4581].
141. Underwood M., Bartlett J., Reeves J., et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?. Cancer Res 1995, 55(11):2422-2430.
142. Jimenez R.E., Hussain M., Bianco F.J., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001, 7(8):2440-2447.
143. Latif Z., Watters A.D., Dunn I., et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003, 89(7):1305-1309.
144. Fleischmann A., Rotzer D., Seiler R., et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011, 60(2):350-357.
145. Press M.F., Plimack E.R., Gomella L.G., et al. HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2. J Clin Oncol 2013, 31(suppl 6):292.
146. Lae M., Couturier J., Oudard S., et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010, 21(4):815-819.
147. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007, 25(16):2218-2224.
148. Sawant S.P., Banumathy S., Daddi A., et al. Pulmonary embolism in cancer patients. Indian J Cancer 2012, 49(1):119-124.
149. Thaler J., Ay C., Pabinger I. Venous thromboembolism in cancer patients-risk scores and recent randomised controlled trials. Thromb Haemost 2012, 108(6):1042-1048.
150. Halton J., Nagel K., Brandao L.R., et al. Do children with central venous line (CVL) dysfunction have increased risk of symptomatic thromboembolism compared to those without CVL-dysfunction, while on cancer therapy?. BMC Cancer 2012, 12:314.
151. Neal D.E., Marsh C., Bennett M.K., et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985, 1(8425):366-368.
152. Colquhoun A.J., Mellon J.K. Epidermal growth factor receptor and bladder cancer. Postgrad Med J 2002, 78(924):584-589.
153. Chaux A., Cohen J.S., Schultz L., et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012, 43(10):1590-1595.
154. Mellon K., Wright C., Kelly P., et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995, 153(3 Pt 2):919-925.
155. Kassouf W., Black P.C., Tuziak T., et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008, 179(1):353-358.
156. Kramer C., Klasmeyer K., Bojar H., et al. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007, 109(10):2016-2024.
157. Kim W.T., Kim J., Yan C., et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol 2014, 25(5):974-979.
158. Pruthi R.S., Nielsen M., Heathcote S., et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010, 106(3):349-354.
159. Strowd R.E., Knovich M.A., Lesser G.J. The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies. Curr Treat Options Oncol 2012, 13(4):451-464.
160. Wong Y.N., Litwin S., Vaughn D., et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012, 30(28):3545-3551.
161. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15(7):807-826.
162. Garcia J.A., Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7(6):1347-1354.
163. Balar A.V., Iyer G., Al-Ahmadie H., et al. Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC). J Clin Oncol 2012, 30(suppl 5). [abstr 277].
164. Milowsky M.I., Iyer G., Regazzi A.M., et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013, 112(4):462-470.
165. Seront E., Rottey S., Sautois B., et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012, 23(10):2663-2670.
166. Iyer G., Hanrahan A.J., Milowsky M.I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338(6104):221.
167. Wagle N., Grabiner B.C., Van Allen E.M., et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014, 4(5):546-553.
168. Mandala M., Grosso F., Vitalini C., et al. Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. Br J Cancer 2012, 107(4):612-616.
169. Reinke C.E., Karakousis G.C., Hadler R.A., et al. Incidence of venous thromboembolism in patients undergoing surgical treatment for malignancy by type of neoplasm: an analysis of ACS-NSQIP data from 2005 to 2010. Surgery 2012, 152(2):186-192.
170. Drosik A., Trzepiora B., Kozielski J. Thromboembolic venous disease as a first sign of neoplastic disease-a case report. Wiad Lek 2012, 65(1):15-18.
171. Lovely J.K., Nehring S.A., Boughey J.C., et al. Balancing venous thromboembolism and hematoma after breast surgery. Ann Surg Oncol 2012, 19(10):3230-3235.
172. Kyriazi V. Breast cancer as an acquired thrombophilic state. J Breast Cancer 2012, 15(2):148-156.
173. Drieskens O., Oyen R., Van Poppel H., et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005, 32(12):1412-1417.
174. 18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009, 27(26):4314-4320.
175. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 2014, 83(2):393-398.
176. Apolo A.B., Riches J., Schoder H., et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010, 28(25):3973-3978.
177. Martinez-Pineiro J.A., Gonzalez Martin M., Arocena F., et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995, 153(3 Pt 2):964-973.
178. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29(16):2171-2177. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al.
179. Herchenhorn D., Dienstmann R., Peixoto F.A., et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol 2007, 33(5):630-638. [discussion 8].
180. Plimack E.R., Hoffman-Censits J.H., Viterbo R., et al. Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: results of a multicenter phase II study. J Clin Oncol 2012, 30(15S):4526. [ASCO meeting abstracts].
181. Scosyrev E., Messing E.M., van Wijngaarden E., et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012, 118(1):72-81.
182. Kaneko G., Kikuchi E., Matsumoto K., et al. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. Jpn J Clin Oncol 2011, 41(7):908-914.
183. Pal S.K., Ruel N.H., Wilson T.G., et al. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer 2012, 10(4):246-250.
184. Stockle M., Meyenburg W., Wellek S., et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995, 153(1):47-52.
185. Freiha F., Reese J., Torti F.M. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996, 155(2):495-499. [discussion 9-500].
186. Paz-Ares L.G., Solsona E., Esteban E., et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010, 28(Suppl 18). [LBA4518, ASCO meeting abstracts].
187. Lehmann J., Kuehn M., Fischer C., et al. Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00). J Clin Oncol 2013, 31(6S):250. [ASCO meeting abstracts].
188. Kaufman D.S., Shipley W.U., Griffin P.P., et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993, 329(19):1377-1382.
189. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996, 14(1):119-126.
190. Kachnic L.A., Kaufman D.S., Heney N.M., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997, 15(3):1022-1029.
191. Fellin G., Graffer U., Bolner A., et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 1997, 80(1):44-49.
192. Rodel C., Grabenbauer G.G., Kuhn R., et al. Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 2002, 52(5):1303-1309.
193. Hagan M.P., Winter K.A., Kaufman D.S., et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003, 57(3):665-672.
194. Zapatero A., Martin de Vidales C., Arellano R., et al. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 2010, 28(4):368-374.
195. Choudhury A., Swindell R., Logue J.P., et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011, 29(6):733-738.
196. James N.D., Hussain S.A., Hall E., et al. Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 2010, 28(15S):4517. [ASCO meeting abstracts].